Search

Recombinant adeno-associated virus (AAV) is currently the most widely used platform for in vivo gene therapy. Clinical pharmacology is a central field for AAV gene therapy, represented by the pillars of pharmacokinetics, pharmacodynamics/efficacy, and safety. In this review, we provide a comprehensive summary of clinical pharmacology considerations for recombinant AAV. The main topics covered are biodistribution and shedding, dose-exposure-response relationship, safety, immune and stress response, and clinical dose selection strategies. We highlight how the cumulative knowledge of AAV gene therapy could help with guiding clinical trial design and assessing and mitigating risks, as well as planning and executing pharmacokinetic/pharmacodynamic /safety data analyses. In addition, we discuss the major gaps and areas of growth in clinical pharmacology understanding of recombinant AAV. These include the mechanisms of the durability of treatment response and variability in biodistribution, transduction, and immunogenicity, as well as a potential influence on AAV's safety and efficacy profiles by drug product characteristics and patient intrinsic/extrinsic factors.

Maribavir is in phase 3 clinical development for treatment of cytomegalovirus infection/disease in transplant recipients. Previous research conducted using only intact cynomolgus monkeys indicated biliary secretion as the primary elimination pathway for maribavir and that maribavir undergoes enterohepatic recirculation (EHR). To clarify the exact mechanisms of maribavir’s EHR behavior, we studied its clearance pathways using intravenously administered 14C-labeled maribavir in intact and bile duct–cannulated (BDC) monkeys and constructed a semi–physiologically based pharmacokinetic (PBPK) model. Total radioactivity metabolite profiles in plasma and excreta were quantitatively determined along with plasma maribavir concentrations. Intact animals showed significantly lower clearance and longer half-lives in both total radioactivity and parent concentration in plasma than BDC monkeys. The primary in vitro and in vivo metabolic pathway for maribavir in monkey is direct glucuronidation; N-dealkylation and renal clearance are minor pathways. In BDC monkeys, 73% of dose was recovered as maribavir glucuronides in bile, and 3% of dose was recovered as parent in bile and feces; in intact animals’ feces, 58% of dose was recovered as parent, and no glucuronides were detected. Therefore, EHR of maribavir occurs through biliary secretion of maribavir glucuronides, and this is followed by hydrolysis of glucuronides in the gut lumen and subsequent reabsorption of parent. A semi-PBPK model constructed from physiologic, in vitro, and in vivo BDC monkey data is capable of projecting maribavir’s pharmacokinetic and EHR behavior in intact animals after intravenous or oral dosing and could be applied to modeling other xenobiotics that are subject to similar EHR processes. SIGNIFICANCE STATEMENT Through both mass balance and semi–physiologically based pharmacokinetic (semi-PBPK) modeling approaches, this study mechanistically and quantitatively elucidates maribavir’s enterohepatic recirculation (EHR) behavior in monkeys, which occurs via extensive direct glucuronidation, biliary secretion of these glucuronides, luminal hydrolysis of glucuronides to parent, and subsequent reabsorption of the parent. The study also identifies important drug- and animal-specific parameters that determine the EHR kinetics, and the semi-PBPK model is readily applicable to other drugs that undergo similar metabolic and recirculation mechanisms.

Given the recent success of gene therapy modalities and the growing number of cell and gene-based therapies in clinical development across many different therapeutic areas, it is evident that this evolving field holds great promise for the unmet medical needs of patients. The recent approvals of Luxturna® and Zolgensma® prove that recombinant adeno-associated virus (rAAV)-based gene therapy is a transformative modality that enables curative treatment for genetic disorders. Over the last decade, Takeda has accumulated significant experience with rAAV-based gene therapies, especially in the early stage of development. In this review, based on the learnings from Takeda and publicly available information, we aim to provide a guiding perspective on Drug Metabolism and Pharmacokinetics (DMPK) substantial role in advancing therapeutic gene therapy modalities from nonclinical research to clinical development, in particular the characterization of gene therapy product biodistribution, elimination (shedding), immunogenicity assessment, multiple platform bioanalytical assays, and first-in-human (FIH) dose projection strategies.

The prodrug strategy has been frequently employed as a chemical approach for overcoming the disadvantages of existing parent drugs. In this report, we synthesized four monoester prodrugs of ganciclovir, an anticytomegalovirus drug, and demonstrated their potential advantages in protease-targeted activation and biopharmaceutical profiles over the parent compound. We demonstrated that these four prodrugs of ganciclovir, i.e., N-benzyloxycarbonyl-(L)-alanine-ganciclovir (CbzAlaGCV), N-benzyloxycarbonyl-(α,l)-aminobutyric acid-ganciclovir (CbzAbuGCV), N-acetyl-(l)-phenylalanine-(l)-alanine-ganciclovir (AcPheAlaGCV), and N-acetyl-(l)-phenylalanine-(α,l)-aminobutyric acid-ganciclovir (AcPheAbuGCV), are hydrolytically activated by the protease of human cytomegalovirus (hCMV), a serine protease that possesses intrinsic esterase activities. CbzAlaGCV and AcPheAlaGCV were found to be activated at a higher rate by the hCMV protease than CbzAbuGCV and AcPheAbuGCV. These ganciclovir prodrugs could potentially be targeted to selective activation by the hCMV protease which is only present at the viral infection sites, thereby achieving higher efficacy and lower systemic toxicity. The tissue stability, cellular uptake, and trans-epithelial transport of these ganciclovir prodrugs were also characterized. The N-acetylated dipeptide prodrugs of ganciclovir were found to be generally more stable than Cbz-amino acid prodrugs in various tissue matrices. Among the four prodrug candidates, AcPheAbuGCV was the most stable in human cell homogenates, plasma, and pooled liver microsomes. AcPheAbuGCV also possessed a superior cellular uptake profile and permeability across epithelial cell monolayers. Since the targeting and selective activation of a prodrug is determined by not only its rate of hydrolysis catalyzed by the hCMV protease target but also its biopharmaceutical properties, i.e., oral absorption and systemic availability, AcPheAbuGCV is considered the best overall candidate among the four ganciclovir prodrugs for further research and development for treatment of hCMV infection.

Introduction: Adeno-associated virus (AAV)-based factor IX (FIX) gene therapy has the potential to provide clinical benefit in patients with hemophilia B. TAK-748 is a novel next-generation AAV vector for FIX gene therapy. The vector design includes the insertion of 3 hepatocyte-specific cis-regulatory elements to increase the strength of the liver-specific transthyretin promoter driving expression of a human FIX transgene. Aims: The objectives of this study were to investigate the TAK-748 dose-response relationship for FIX activity, and evaluate its efficacy, in FIX knockout (KO) mice and rhesus monkeys. Methods: Male FIX KO mice (N=12/group) received single intravenous doses of TAK-748 (7.4×1010, 1.5×1011, 7.4×1011, or 1.5×1012 vector genomes [vg]/kg) or buffer. Blood samples were taken on days 7, 14, 28, 42, and 56 for the analysis of plasma FIX activity. At the end of the observation period, the bleeding phenotype was assessed by a tail-tip bleeding assay. The viral transduction efficiency of TAK-748 in liver tissue was analyzed by quantitative real-time polymerase chain reaction. Safety assessments included monitoring for clinical signs, and histopathological analysis of selected organs (liver, spleen, kidney, and heart). Male rhesus monkeys (N=3/group) were administered single TAK-748 intravenous bolus injections (3.8×1011, 9.5×1011, or 1.9×1012 vg/kg). Blood samples were collected before dosing and weekly after dosing up to week 18. Plasma FIX activity, human (hu)FIX antigen, and anti-hu-Padua FIX neutralizing antibodies were analyzed. Results: No clinical signs or deaths were recorded in animals treated with TAK-748, and there were no TAK-748-related histopathological findings in the tissues collected from the mice. FIX activity levels in plasma from FIX KO mice treated with buffer were below the lower limit of quantification. Administration of TAK-748 resulted in a dose-dependent increase in mean plasma FIX activity, and supraphysiologic mean FIX levels up to 41.0 IU/mL (1.5×1012 vg/kg). In the tail-tip bleeding assay, blood loss was significantly reduced in the TAK-748 groups at dose levels above 7.4×1010 vg/kg (P Administration of TAK-748 to rhesus monkeys resulted in a dose-dependent increase in mean plasma FIX activity and antigen, and peak levels of huFIX expression were detected 2-4 weeks after treatment. Mean huFIX activity was 0.3, 0.6, and 1.9 IU/mL after treatment with 3.8×1011 vg/kg, 9.5×1011 vg/kg, and 1.9×1012 vg/kg TAK-748, respectively. A significant reduction in FIX activity and huFIX protein was observed in most of the animals starting about 4 weeks after dosing with TAK-748. In most animals, anti-huFIX Padua neutralizing antibody titers were detected at about week 6 of the study and correlated with the preceding reductions in huFIX expression. Conclusions: Treatment with TAK-748 resulted in dose-dependent increases in plasma FIX activity and was efficacious in FIX KO mice and rhesus monkeys. There were no treatment-related safety findings. Disclosures Weiller: Baxalta Innovations GmbH, a Takeda company: Employment. Wang:Shire US Inc., a Takeda company: Employment, Equity Ownership. Coulibaly:Baxalta Innovations GmbH, a Takeda company: Employment. Schuster:Baxalta Innovations GmbH, a Takeda company: Employment. Rottensteiner:Baxalta Innovations GmbH, a Takeda company: Employment, Equity Ownership. Sun:Shire US Inc., a Takeda company: Employment. Chuah:Shire, a Takeda company: Consultancy, Research Funding; Catalyst Bio: Consultancy, Research Funding; Pfizer: Research Funding. Vandendriessche:Shire, a Takeda company: Consultancy, Honoraria, Research Funding; Catalyst Bio: Consultancy, Research Funding; Pfizer: Research Funding; Biotest: Honoraria. Scheiflinger:Baxalta Innovations GmbH, a Takeda company: Employment, Equity Ownership. Höllriegl:Baxalta Innovations GmbH, a Takeda company: Employment, Equity Ownership.

At present, the development of health care industry is also very vigorous and prosperous, and has become one of the most widely developed industries in the world. Medical centers and service centers in various regions have begun to transform from medical model to health care model. This field programmable gate array has great advantages in this respect, and it is also one of the principles of patient-centered nursing. With the vigorous development of machine learning, its application scope is more and more extensive, and its application in medicine is also very common. People use machine learning to process big data in the medical field. In order to better manage patient data and realize patient-centered, we must analyze a large number of health data. The traditional management tools are not enough to support the analysis of modern data. Therefore, we should use advanced big data processing technology for relevant data processing, and use updated tools to meet the current medical needs. The signal processing based big data evaluation is to be done through FPGA. The proposed system contains three process these process are executed through the machine learning based. The first process preprocessing is used eliminate the noise of the image or irrelevant data avoided. The second process feature selection based decision tree technique used and then after the final process classification stage based machine learning technique is used to analysis of the big data accuracy level. FPGA based machine technique used to achieve the better result of the proposed system.

Introduction Maribavir, a potent and orally bioavailable antiviral, is being evaluated in Phase 3 trials for the treatment of cytomegalovirus (CMV) infections in transplant patients. Often numerous concomitant medications are administered to these patients to manage their comorbidities. A thorough evaluation of maribavir potential for drug–drug interactions (DDIs) is warranted and required for the regulatory approval. Objectives To thoroughly evaluate potential DDIs for maribavir. Methods Extensive in vitro studies were conducted to evaluate the potential involvement of cytochrome P450s (CYPs), uridine diphosphate glucuronosyltransferases (UGTs) and transporters on the disposition of maribavir, as well as the inhibitory and induction effect of maribavir on these enzymes and transporters. Clinical Phase 1 studies included a human mass-balance study, two probe-cocktail studies, and five DDI studies with ketoconazole, rifampin, antacid, voriconazole, and tacrolimus. Results Maribavir is metabolized primarily in the liver through CYP3A4 (70–85%) and CYP1A2 (15–30%). Renal clearance is a minor route ( Conclusions Maribavir has low risk for DDI. Inhibitors of CYP3A4 and/or P-gp may increase maribavir exposure, but dose adjustment of maribavir is not necessary. Potent inducers of CYP3A4 and P-gp decrease maribavir exposure, necessitating maribavir dose increase. Maribavir may increase exposure of immunosuppressants, such as tacrolimus. Therefore, monitoring of concomitant immunosuppressants' blood concentration should be considered at initiation, co-administration, and discontinuation of maribavir. Maribavir is not expected to interact with other concurrent medications.

Introduction Maribavir is a potent and orally bioavailable antiviral with a novel mechanism of action against cytomegalovirus (CMV). The efficacy and safety of maribavir for treatment of CMV infections are being evaluated in ongoing Phase 3 trials. Characterization of drug–drug interaction (DDI) properties of maribavir is necessary in informing potential DDIs with co-medications. Objective To evaluate the potential cytochrome p450 and p-glycoprotein–mediated drug–drug interaction by maribavir. Methods Cytochrome P450 (CYP) reversible inhibition: Probe substrates of CYPs were incubated with human liver microsomes (HLM) and maribavir. Percent remaining CYP activity was plotted against maribavir concentrations for IC50 determination. Time-dependent inhibition (TDI) for CYPs: After pre-incubation with maribavir for varying durations, percent remaining CYP activity in HLM was measured. The concentration at half-maximal inactivation (KI) and maximum inactivation rate constant (kinact) were calculated. CYP induction: After treating human hepatocytes with maribavir for three days, CYP mRNA expression was plotted against maribavir concentrations to determine half-maximal induction concentration (EC50) and maximal fold induction (Emax). P-glycroprotein (P-gp) inhibition: Bi-directional transport of digoxin in Caco-2 cells with maribavir was measured and IC50 calculated by plotting percent transporter activity against maribavir concentration. Results Maribavir is not a reversible inhibitor of CYP2A6, CYP2B6, CYP2C8, CYP2D6, CYP2E1, or CYP3A4 and is a weak inhibitor of CYP1A2, CYP2C9, and CYP2C19 (IC50 40, 18, and 35 µM). Maribavir is not a TDI of CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 but a weak TDI for CYP3A (KI 41.2 μM, kinact 0.0117 min−1). Maribavir is not an inducer of CYP1A2 or CYP2B6 mRNA but is a weak, possibly donor-dependent inducer of CYP3A4 mRNA. Maribavir is a weak inhibitor of P-gp (IC50 33.7 µM). Conclusions Maribavir is not expected to affect exposures of substrates of major CYPs or P-gp when co-administered at therapeutic dose of 400 mg BID, based on its estimated maximal unbound plasma concentration (Cmax,u) of 0.74 μM in transplant patients with CMV infection.

Introduction Maribavir, a potent and orally bioavailable antiviral, is being evaluated in Phase 3 trials for the treatment of CMV infections in transplant patients and received FDA Breakthrough Therapy designation. A thorough understanding of the clinical pharmacology of maribavir is necessary to guide the appropriate use of the drug in transplant patients who often have multiple comorbidities and require complex concurrent medication regimens. Objectives To summarize the clinical pharmacology data of maribavir. Methods Pharmacokinetic and pharmacodynamic assessments were performed in sixteen Phase 1 studies and three Phase 2 studies. Data were summarized to characterize maribavir's disposition (absorption, distribution, metabolism, and excretion) in healthy adult subjects and special populations (HIV-infected, hepatically impaired, renally impaired, and organ transplant recipients). A definitive QT study was conducted to evaluate the cardiac repolarization effect. The drug interaction risks were assessed using both nonclinical and clinical studies. Results Maribavir is primarily eliminated through the CYP3A4 pathway and has a half-life of 5–7 hours. Co-administration with food or antacid, or crushing the tablet, had no impact on maribavir's exposure. Maribavir binds to plasma proteins with unbound fraction estimated at 1.5% and can penetrate the blood–retinal barrier. No pharmacokinetic difference is found among healthy subjects, transplant patients, subjects with severe renal impairment, or moderate hepatic impairment. Maribavir's exposure is increased by 46% by ketoconazole and decreased by 61% by rifampin. Maribavir increases tacrolimus exposure by 51%, does not affect voriconazole exposure, and is not expected to affect exposures of most other concurrent medications. Maribavir has no effects on QT intervals. Conclusions Extensive clinical pharmacology data have been generated to support the clinical use and dose of maribavir for the treatment of CMV infections in transplant recipients. Maribavir can be taken with or without food. No maribavir dose adjustment is needed in patients with mild-to-moderate hepatic impairment or renal impairment or with concurrent medications, except for CYP3A4 inducers.

This paper presents a simulation method of hyper-spectral dynamic scene and image sequence for hyper-spectral equipment evaluation and target detection algorithm. Because of high spectral resolution, strong band continuity, anti-interference and other advantages, in recent years, hyper-spectral imaging technology has been rapidly developed and is widely used in many areas such as optoelectronic target detection, military defense and remote sensing systems. Digital imaging simulation, as a crucial part of hardware in loop simulation, can be applied to testing and evaluation hyper-spectral imaging equipment with lower development cost and shorter development period. Meanwhile, visual simulation can produce a lot of original image data under various conditions for hyper-spectral image feature extraction and classification algorithm. Based on radiation physic model and material characteristic parameters this paper proposes a generation method of digital scene. By building multiple sensor models under different bands and different bandwidths, hyper-spectral scenes in visible, MWIR, LWIR band, with spectral resolution 0.01μm, 0.05μm and 0.1μm have been simulated in this paper. The final dynamic scenes have high real-time and realistic, with frequency up to 100 HZ. By means of saving all the scene gray data in the same viewpoint image sequence is obtained. The analysis results show whether in the infrared band or the visible band, the grayscale variations of simulated hyper-spectral images are consistent with the theoretical analysis results.

The design of the collimator for dynamic infrared (IR) scene simulation based on the digital micro-mirror devices (DMD) is present in this paper. The collimator adopts a reimaging configuration to limit in physical size availability and cost. The aspheric lens is used in the relay optics to improve the image quality and simplify the optics configuration. The total internal reflection (TIR) prisms is located between the last surface of the optics and the DMD to fold the raypaths of the IR light source. The optics collimates the output from 1024×768 element DMD in the 8~10.3μm waveband and enables an imaging system to be tested out of 8° Field Of View (FOV). The long pupil distance of 800mm ensures the remote location seekers under the test.

This study was designed to increase the throughput of rat brain microdialysis studies by administration of compounds as a cassette as opposed to discrete study. Eight compounds (carbamazepine, citalopram, desmethylclozapine, diphenhydramine, gabapentin, metoclopramide, naltrexone, and stavudine) were selected and administered as an intravenous bolus dose at 0.5–3.3 mg/kg each followed by an intravenous infusion at 1 mg/kg per hour for 6 hours in rats in a cassette or discrete dosing. The dialysate, plasma, brain, and cerebrospinal fluid were collected and analyzed using liquid chromatography–tandem mass spectrometry. The microdialysis probe recovery was determined by an in vitro gain method. The recovery between the cassette and discrete dosing was similar, with an average of 1.0 ± 0.10–fold difference. The stavudine interstitial fluid (ISF) concentration, as measured by brain microdialysis, was below the low limit of quantitation and was excluded from the analyses. The ratios of ISF concentration to unbound plasma concentration were within 2-fold for six of the remaining seven compounds, with an average of 0.92 ± 0.51–fold difference between the cassette and discrete methods. The ratios of ISF concentration to unbound brain concentration, as measured by the brain homogenate method, were also similar, with a 1.1 ± 0.7–fold difference. In addition, the ratios of ISF to cerebrospinal fluid concentrations were similar, with a 1.5 ± 0.6–fold difference. The results from this study support the use of a cassette dosing approach to enhance the throughput of rat brain microdialysis studies in drug discovery.

The paper presents a hardware in loop dynamic IR scene simulation technology for IR hyperspectral imaging system. Along with fleetly development of new type EO detecting, remote sensing and hyperspectral imaging technique, not only static parameters’ calibration of hyperspectral IR imaging system but also dynamic parameters’ testing and evaluation are required, thus hyperspectral dynamic IR simulation and evaluation become more and more important. Hyperspectral dynamic IR scene projector utilizes hyperspectral space and time domain features controlling spectrum and time synchronously to realize hardware in loop simulation. Hyperspectral IR target and background simulating image can be gained by the accomplishment of 3D model and IR characteristic romancing, hyperspectral dynamic IR scene is produced by image converting device. The main parameters of a developed hyperspectral dynamic IR scene projector: wave band range is 3~5μm, 8~12μm; Field of View (FOV) is 8°; spatial resolution is 1024×768; spectrum resolution is 1%~2%. IR source and simulating scene features should be consistent with spectrum characters of target, and different spectrum channel’s images can be gotten from calibration. A hyperspectral imaging system splits light with dispersing type grating, pushbrooms and collects the output signal of dynamic IR scene projector. With hyperspectral scene spectrum modeling, IR features romancing, atmosphere transmission feature modeling and IR scene projecting, target and scene in outfield can be simulated ideally, simulation and evaluation of IR hyperspectral imaging system’s dynamic features are accomplished in laboratory.

Airborne Forward looking infra-red (FLIR) searcher simulation system can provide multi-mode simulated test environment that almost actual field environment, and can simulate integrated performance and external interface of airborne FLIR simulation system. Furthermore, the airborne FLIR searcher simulation system can support the algorithm optimization of image processing, and support the test and evaluation of electro-optical system, and also support the line test of software and evaluate the performance of the avionics system. The detailed design structure and information cross-linking relationship of each component are given in this paper. The simulation system is composed of the simulation center, the FLIR actuator, the FLIR emulator, and the display control terminal. The simulation center can generate the simulated target and aircraft flying data in the operation state of the airborne FLIR Searcher. The FLIR actuator can provide simulation scene. It can generate the infrared target and landform based scanning scene, response to the commands from simulation center and the FLIR actuator and operation control unit. The infrared image generated by the FLIR actuator can be processed by the FLIR emulator using PowerPC hardware framework and processing software based on VxWorks system. It can detect multi-target and output the DVI video and the multi-target detection information which corresponds to the working state of the FLIR searcher. Display control terminal can display the multi-target detection information in two-dimension situation format, and realize human-computer interaction function.

The airborne multispectral imaging fusion detection technology is proposed in this paper. In this design scheme, the airborne multispectral imaging system consists of the multispectral camera, the image processing unit, and the stabilized platform. The multispectral camera can operate in the spectral region from visible to near infrared waveband (0.4-1.0um), it has four same and independent imaging channels, and sixteen different typical wavelengths to be selected based on the different typical targets and background. The related experiments were tested by the airborne multispectral imaging system. In particularly, the camouflage targets were fused and detected in the different complex environment, such as the land vegetation background, the desert hot background and underwater. In the spectral region from 0.4 um to 1.0um, the three different characteristic wave from sixteen typical spectral are selected and combined according to different backgrounds and targets. The spectral image corresponding to the three characteristic wavelengths is resisted and fused by the image processing technology in real time, and the fusion video with typical target property is outputted. In these fusion images, the contrast of target and background is greatly increased. Experimental results confirm that the airborne multispectral imaging fusion detection technology can acquire multispectral fusion image with high contrast in real time, and has the ability of detecting and identification camouflage objects from complex background to targets underwater.

Purpose: To determine occurrence and determinants of resistant hypertension (RHT) among patients attending cardiology clinic of the affiliated hospital of Hangzhou Normal University, China. Methods: An observational prospective cross-sectional study was conducted among patients with hypertension attending the cardiology clinic over a period of 6 months. After identification of patients with RHT, various independent co-variants were tested by logistic regression in order to evaluate the determinants of RHT. Results: Out of 556 patients, 104 (18.7 %) patients had RHT while 67 (12.1 %) patients had uncontrolled blood pressure (BP) in spite of treatment with three antihypertensive drugs including a diuretic; 37 (6.6 %) patients had controlled BP with > three drugs. Obesity (OR: 2.7, p = 0.002], duration of hypertension (OR: 1.8, p = 0.015], presence of diabetes mellitus (OR: 3.6, p < 0.001) and ischemic heart disease (OR: 3.2, p = 0.001) were significant determinants of resistant hypertension in the study cohort. Conclusion: The prevalence of RHT found in this study is significantly high, thus indicating a need for greater attention of clinicians to this highly morbid condition. Obese patients and those suffering from diabetes mellitus, ischemic heart disease and chronic diseases should be evaluated for the presence of RHT. Early identification of such patients will provide sufficient time for clinicians to refer patients, as well as modify and/or intensify therapy. Keywords: Resistant hypertension, Risk factors, Hypertension, Stroke, Diabetes mellitus, Ischemic heart disease

Multispectral imaging detecting technology use target radiation character in spectral spatial distribution and relation between spectral and image to detect target and remote sensing measure. Its speciality is multi channel, narrow bandwidth, large amount of information, high accuracy. The ability of detecting target in environment of clutter, camouflage, concealment and beguilement is improved. At present, spectral imaging technology in the range of multispectral and hyperspectral develop greatly. The multispectral imaging equipment of unmanned aerial vehicle can be used in mine detection, information, surveillance and reconnaissance. Spectral imaging spectrometer operating in MWIR and LWIR has already been applied in the field of remote sensing and military in the advanced country. The paper presents the technology of multispectral imaging. It can enhance the reflectance, scatter and radiation character of the artificial targets among nature background. The targets among complex background and camouflage/stealth targets can be effectively identified. The experiment results and the data of spectral imaging is obtained.